Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer

Clinical Breast Cancer

Volumn 10, Issue 4, 2010, Pages 267-274

  Delea, Thomas ^a   Taneja, Charu ^a   Sofrygin, Oleg ^a   Kaura, Satyin ^b   Gnant, Michael ^c  

^a POLICY ANALYSIS INC PAI   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adjuvant therapy; Bisphosphonates; Quality adjusted life year; Recurrence free survival

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; GOSERELIN; TAMOXIFEN; ZOLEDRONIC ACID;

ADD ON THERAPY; ADULT; AGED; ARTHRALGIA; ARTICLE; BONE PAIN; BREAST CANCER; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG COST; EARLY CANCER; FEMALE; FEVER; FOLLOW UP; HEALTH CARE COST; HEALTH CARE SYSTEM; HIDDEN MARKOV MODEL; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREMENOPAUSE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; UNITED STATES;

EID: 77955609830     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.034     Document Type: Article

References (44)

1. Rosen LS, Gordon D, Antonio BS, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7:377-387
2. Bundred NJ, Campbell ID, Davidson N, et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 2008; 112:1001-1010
3. Brufsky A, Harker WG, Beck J T, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007; 25:829-836
4. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008; 9:840-849
5. Gnant M F, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25:820-828
6. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356:1809-1822
7. Avilés A, Nambo MJ, Neri N, et al. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007; 24:227-230
8. Daubiné F, Le Gall C, Gasser J, et al. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007; 99:322-330
9. Lin A, Park J, Melisko M, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. Paper presented at: the 6th European Breast Cancer Conference (EBCC-6); Berlin, Germany; 2009; 15-19.
10. Mystakidou K, Katsouda E, Parpa E, et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005; 22:195-201.
11. Santini D, Vincenzi B, Galluzzo S, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007; 13:4482-4486
12. Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Oncol 2003; 21:28-34.
13. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the International Expert Consensus on the Primary Therapy of Early Breast Cancer 2007. Ann Oncol 2007; 18:1133-1144
14. Breast cancer. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-v.2. National Comprehensive Cancer Network [Web site]. Available at: http://www.nccn.org/index.asp. Accessed: December 16, 2008.
15. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer [erratum published in: N Engl J Med 2009; 360:23]. N Engl J Med 2009; 360:679-691
16. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13:322-338
17. Allison PD. Survival Analysis Using SAS: A Practical Guide. Cary, NC: SAS Institute Inc; 1995.
18. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351:1451-1467
19. Delea TE, Karnon J, Sofrygin O, et al. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmeno-pausal women with early-stage breast cancer. Clin Breast Cancer 2007; 7:608-618
20. Kljin JG, Blamey B, Tominaga T, et al. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001; 19:343-353
21. Arias E. United States Life Table, 2004. Natl Vital Stat Rep 2007; 56:1-39.
22. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Death from each cause: United States, 2005. Available at http://www. cdc.gov/nchs/data/dvs/mortfinal2005-WorktableorigI.pdf. Accessed: December 16, 2008.
23. Thomson Healthcare Inc. Drug Topic Red Book. Thomson Healthcare Inc; 2008.
24. U.S. Department of Health and Human Services, Centers for Medicare and Med-icaid Services. PFS National Payment Amount File. Available at: http://www.cms. hhs.gov/PhysicianFeeSched/PFSNPAF/list.asp. Accessed: December 16, 2008.
25. Lamerato L, Havstad S, Gandhi S, et al. Economic burden associated with breast cancer recurrence: Findings from a retrospective analysis of health system data. Cancer 2006; 106:1875-1882
26. U.S. Department of Health and Human Services, Centers for Medicare and Medic-aid Services. FY 2004 PPS Payment Impact File. Available at http://www.cms.hhs. gov/AcuteInpatientPPS/HIF/list.asp#TopofPage. Accessed: December 16, 2008.
27. U.S. Bureau of Labor Statistics. Consumer Price Index. Measuring Price Change for Medical Care in the CPI. Available at: http://data.bls.gov/cgi-bin/ print.pl/cpi/cpifact4.htm. Accessed: December 16, 2008.
28. Sorensen S, Brown R, Benedict A, et al. Patient-rated utilities in postmenopausal early breast cancer (EBC): a cross-country comparison. Value Health 2004; 7:641-642
29. Briggs A. Probabilistic analysis of cost-effectiveness models: Statistical representation of parameter uncertainty. Value Health 2005; 8:1-2.
30. Locker GY, Mansel R, Cella D, et al. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat 2007; 106:229-238 (Pubitemid 350045007)
31. Delea TE, Karnon J, Smith RE, et al. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care 2006; 12:374-386
32. Thompson D, Taylor DC, Montoya EL, et al. Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer. Value Health 2007; 10:367-376
33. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making 2000; 20:332-342
34. Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med 2003; 163:1637-1641
35. Levine MN, Ganz PA, Haller DG. Economic evaluation in the Journal of Clinical Oncology: past, present, and future. J Clin Oncol 2007; 25:614-616
36. Stokes ME, Thompson D, Montoya EL, et al. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-Medicare data. Value Health 2008; 11:213-220
37. Remák E. In Reply. Cost effectiveness of sunitinib. J Clin Oncol 2008; 26:5829-5830
38. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999; 18:341-364
39. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 2000; 355:1757-1770
40. Cuzick J, Stewart H, Rutqvist L, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994; 12:447-453
41. Patt DA, Goodwin JS, Kuo Y F, et al. Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol 2005; 23:7475-7482
42. Giordano SH, Kuo Y F, Freeman JL, et al. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 2005; 97:419-424
43. Ougari KE, Taneja C, Sofrygin O, et al. Cost-effectiveness of zoledronic (ZOL) acid plus endocrine therapy (ET) in premenopausal women with early breast cancer (EBC) from a Canadian perspective. J Clin Oncol 2009; 27(15 suppl):20s (abstract 557).
44. Delea TE, Taneja C, Kaura S, et al. Cost-effectiveness of adding zoledronic acid to endocrine therapy in premenopausal women with hormone-responsive early breast cancer in Greece, based on the ABCSG-12 Study. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 12th Annual European Congress. Paris, France; 2009.